6533b7cefe1ef96bd12579ea
RESEARCH PRODUCT
Expert opinion on managing chronic HCV in patients with cardiovascular disease
Alessia PepePatrice CacoubMark BondinCristina VassalleSalvatore PettaAntonio Craxìsubject
medicine.medical_specialtyCardiotonic AgentsHepacivirusDisease030204 cardiovascular system & hematologySystemic inflammationAntiviral Agents03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemRisk Factors[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesOdds RatioHumansMedicineDrug InteractionsPharmacology (medical)In patient030212 general & internal medicineRisk factorIntensive care medicineExpert TestimonyCardiovascular mortalityInflammationPharmacologybusiness.industryDisease progressionDisease ManagementHepatitis C Chronic3. Good healthInfectious DiseasesCardiovascular DiseasesExpert opinionPractice Guidelines as TopicDisease riskmedicine.symptombusinessdescription
International audience; Extrahepatic manifestations of chronic HCV infection include cardiovascular diseases and an increase in cardiovascular mortality. The pathogenic mechanisms by which HCV contributes to cardiovascular disease are not well defined, however, it is likely that systemic inflammation, and the promotion of other metabolic diseases are involved. In this Review, the evidence for HCV infection as a non-traditional risk factor for cardiovascular disease is evaluated. Furthermore, practical advice to evaluate cardiovascular disease risk and disease in chronic hepatitis C patients are included for help in daily clinical practice. Despite the advances in therapies for the treatment of HCV, there remains a need for increased awareness among specialists so that patients are more likely to obtain the treatment required to mitigate disease progression.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2018-06-21 |